13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
42 檔
25.8%
During the Q3 2025 filing period, Prosight Management, LP (CIK: 0001617201) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $580.4M across 42 reported positions.
Prosight Management, LP executed strategic sector rebalancing during Q3 2025, establishing 14 new positions while fully exiting 10 holdings and trimming 16 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 9.29% | +2.93% | -35.16% | |
| 2 | MGTX | MeiraGTx Holdings plc | Stock-Other | 7.85% | -3.52% | -10.85% | |
| 3 | ✓ | Adc Therapeutics SA | Stock-Other | 6.97% | -3.66% | -28.62% | |
| 4 | KURA | Kura Oncology Inc | Stock-Other | 5.69% | -0.66% | -13.29% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 5.08% | +0.86% | — | |
| 6 | JANX | Janux Therapeutics Inc | Stock-Other | 4.93% | +1.98% | +1.34% | |
| 7 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.71% | -0.82% | EXIT | |
| 8 | ICLR | ICON Public Limited Company | Stock-Healthcare | 4.47% | — | +11.10% | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.60% | +1.57% | -7.06% | |
| 10 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.20% | — | -44.04% | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.19% | +0.34% | +10.25% | |
| 12 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.14% | — | -50.88% | |
| 13 | DXCM | Dexcom Inc | Stock-Healthcare | 3.06% | — | +178.88% | |
| 14 | STTK | Shattuck Labs Inc | Stock-Other | 3.04% | +1.84% | -17.89% | |
| 15 | ZYME | Zymeworks Inc | Stock-Other | 2.99% | +0.83% | -42.77% | |
| 16 | CON | Concentra Group Holdings Par | Stock-Other | 2.98% | -1.78% | EXIT | |
| 17 | ✓ | Corcept Therapeutics Inc | Stock-Other | 2.86% | — | — | |
| 18 | IMVT | Immunovant Inc | Stock-Other | 2.63% | -0.72% | EXIT | |
| 19 | SEM | Select Medical Holdings CORP | Stock-Other | 2.62% | — | +147.28% | |
| 20 | BHVN | Biohaven Ltd. | Stock-Other | 2.10% | — | +11.30% | |
| 21 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.87% | — | — | |
| 22 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.73% | +1.15% | — | |
| 23 | CDNA | Caredx Inc | Stock-Other | 1.71% | — | +66.45% | |
| 24 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 1.44% | — | +18.03% | |
| 25 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.39% | -0.16% | -14.21% | |
| 26 | KIDS | Orthopediatrics CORP | Stock-Other | 1.33% | -0.27% | +319.17% | |
| 27 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.01% | -0.02% | -40.78% | |
| 28 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.96% | +0.01% | -19.78% | |
| 29 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.64% | -6.94% | — | |
| 30 | ALGN | Align Technology Inc | Stock-Healthcare | 0.57% | — | — | |
| 31 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.57% | — | -85.00% | |
| 32 | TWST | Twist Bioscience CORP | Stock-Other | 0.49% | — | — | |
| 33 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.43% | — | — | |
| 34 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.42% | — | -83.94% | |
| 35 | SGHT | Sight Sciences Inc | Stock-Other | 0.35% | — | -49.53% | |
| 36 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.17% | -0.69% | +67.80% | |
| 37 | SDGR | Schrodinger Inc | Stock-Other | 0.16% | -0.95% | EXIT | |
| 38 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.15% | +0.11% | +32.71% | |
| 39 | TBI | Trueblue Inc | Stock-Other | 0.11% | -0.16% | EXIT | |
| 40 | PRTA | Prothena Corporation plc | Stock-Other | 0.05% | — | -92.53% | |
| 41 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.01% | -0.07% | -97.55% | |
| 42 | ACTU | Actuate Therapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ISRG | Intuitive Surgical Inc | +2.8% | — | Add |
| 2 | ✓ | Adc Therapeutics SA | +2.6% | -28.62% | Trim |
| 3 | BHVN | Biohaven Ltd. | +1.3% | +11.30% | Add |
| 4 | KURA | Kura Oncology Inc | +1.2% | -13.29% | Add |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +1.1% | -7.06% | Add |
| 6 | ICLR | ICON Public Limited Company | +1% | +11.10% | Add |
| 7 | STTK | Shattuck Labs Inc | +1% | -17.89% | Trim |
| 8 | CDNA | Caredx Inc | +0.9% | +66.45% | Add |
| 9 | IMVT | Immunovant Inc | +0.6% | +45.70% | Add |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | 0% | -40.78% | Trim |
| 11 | OKUR | Onkure Therapeutics Inc-a | -0.1% | +67.80% | Add |
| 12 | RNTX | Rein Therapeutics Inc | -0.1% | +32.71% | Add |
| 13 | PLRX | Pliant Therapeutics Inc | -0.1% | -97.55% | Trim |
| 14 | MGTX | MeiraGTx Holdings plc | -0.4% | -10.85% | Add |
| 15 | CTMX | Cytomx Therapeutics Inc | -0.4% | -83.94% | Trim |
| 16 | SGHT | Sight Sciences Inc | -0.4% | -49.53% | Trim |
| 17 | AM6 | Amicus Therapeutics Inc | -0.6% | -50.88% | Add |
| 18 | ZYME | Zymeworks Inc | -0.8% | -42.77% | Trim |
| 19 | TECX | Tectonic Therapeutic Inc | -0.9% | -14.21% | Trim |
| 20 | JANX | Janux Therapeutics Inc | -1.2% | +1.34% | Add |
| 21 | ROIV | Roivant Sciences Ltd. | -1.3% | -26.16% | Trim |
| 22 | ACHC | Acadia Healthcare Co Inc | -1.5% | +18.03% | Trim |
| 23 | LKFT | Lakefront Biotherapeutic-adr | -1.6% | -35.16% | Trim |
| 24 | PRTA | Prothena Corporation plc | -1.6% | -92.53% | Trim |
| 25 | ARGX | Argenx Se - Adr | -2.1% | -85.00% | Trim |
| 26 | RCKT | Rocket Pharmaceuticals Inc | -2.3% | -19.78% | Trim |
| 27 | SDGR | Schrodinger Inc | -2.3% | — | Trim |
| 28 | BBIO | Bridgebio Pharma Inc | -3.7% | -44.04% | Trim |
| 29 | MIRM | Mirum Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 31 | DXCM | Dexcom Inc | — | NEW | New buy |
| 32 | CON | Concentra Group Holdings Par | — | NEW | New buy |
| 33 | ✓ | Corcept Therapeutics Inc | — | NEW | New buy |
| 34 | SEM | Select Medical Holdings CORP | — | NEW | New buy |
| 35 | VRTX | Vertex Pharmaceuticals Inc | — | NEW | New buy |
| 36 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 37 | ABCL | Abcellera Biologics Inc | — | EXIT | Sold out |
| 38 | KIDS | Orthopediatrics CORP | — | NEW | New buy |
| 39 | LIVN | LivaNova PLC | — | EXIT | Sold out |
| 40 | HAE | Haemonetics Corp/mass | — | EXIT | Sold out |
| 41 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 42 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 43 | ALGN | Align Technology Inc | — | NEW | New buy |
| 44 | ADUS | Addus Homecare CORP | — | EXIT | Sold out |
| 45 | TWST | Twist Bioscience CORP | — | NEW | New buy |
| 46 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 47 | ERAS | Erasca Inc | — | EXIT | Sold out |
| 48 | SYRE | Spyre Therapeutics Inc | — | EXIT | Sold out |
| 49 | ✓ | Mural Oncology Pub LTD Co | — | EXIT | Sold out |
| 50 | TBI | Trueblue Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 42 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LKFT, MGTX, ADC THERAPEUTICS SA) accounted for 25.8% of total reported equity market value during Q3 2025.
Top New Position Initiated
CRNX
市值: $13.7M
Top Position Liquidated / Trimmed
MIRM
前期市值: $15.5M
During Q3 2025, Prosight Management, LP's top holdings by market value included LKFT (9.3%)、MGTX (7.8%)、ADC THERAPEUTICS SA (7.0%). The largest single position, LKFT, represented 9.3% of total portfolio value.
In Q3 2025, Prosight Management, LP made 52 total portfolio adjustments, initiating 14 new buys, adding to 12 positions, trimming 16 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.